New Delhi: Fortis Healthcare personal hospital chain and Apollo Hospital have begun managing the Russian vaccine Covid-19 Sputnik V in two hospitals in Delhi-NCR, officials said on Thursday.
Indraprastha Apollo in Delhi has begun managing Sputnik V in a gradual way from June 30.
About 1,000 people have been vaccinated so far, a spokesman said.
“Registration facilities and walk-in in spot for Sputnik V are currently limited, and we encourage beneficiaries to take an appointment with the Cowin application,” the official said.
According to Fortis Healthcare officials, the private hospital chain began giving Jab Sputnik V last week at the Fortis Memorial Research Institute, Gurugaon, and Fortis Hospital, Mohali.
“To speed up drive vaccination, we introduce vaccines at Fortis Escort Hospital, Jaipur, from Friday.
We have received a good response and a total of 2,193 people have been vaccinated until now,” he said.
The official said Fortis Healthcare had received fresh sputnik v supplies which would help improve inoculation drives.
Hospital sources say there have been several delays in the supply of vaccines and can be associated with increased cases in Russia, which have started large-scale vaccination drives for the population.
An official of Madhukar Rainbow Children’s Hospital in Delhi said the facility would receive a sputnik v of the DR reddy laboratory based in Hyderabad, marketing partners for vaccines in this country, in three to four days.
Sputnik V uses two different viruses that cause ordinary flu (adenovirus) in humans.
Two doses, given 21 separate days, differently and cannot be exchanged.
The center has improved vaccine prices with Rs 1,145 per dose.
The maximum covishield price for the Covid-19 Private Vaccination Center (CVCS) has been repaired at Rs 780 per dose, while Covaxin is Rs 1,410 per dose.
Russian national research institute Gamalia epidemiology and microbiology has developed a vaccine and Russian direct investment funds (RDIF) is marketing globally.
Laboratory Dr.
Reddy has imported a shot from Russia.
During a certain period of time, this vaccine will also be produced in India.
According to Gamaleya and RDIF, Sputnik V has indicated the level of efficacy of 92 percent.